Humira Biosimilar Landscape
| Biosimilar | Manufacturer | List Price vs. Humira | Interchangeable? |
|---|---|---|---|
| Hadlima (adalimumab-bwwd) | Samsung Bioepis/Organon | ~85% discount | Yes |
| Hyrimoz (adalimumab-adaz) | Sandoz | ~85% discount | Yes |
| Cyltezo (adalimumab-adbm) | Boehringer Ingelheim | ~85% discount | Yes |
| Yusimry (adalimumab-aqvh) | Coherus | ~85% discount | Yes |
AbbVie's Rebate Strategy
AbbVie has responded to biosimilar competition with aggressive rebate strategies — offering large rebates to PBMs and employers who maintain Humira on preferred formulary. The rebates can be substantial — sometimes making Humira's net cost competitive with biosimilars. Employers must carefully evaluate the net cost of Humira vs. biosimilars, including all rebates, to determine the most cost-effective option.
Net Cost Analysis
IQ Insight
The Humira biosimilar decision requires a careful net cost analysis. AbbVie's rebates can make Humira's net cost competitive with biosimilars — but only if the employer receives 100% of the rebates. If the PBM retains a portion of Humira rebates, the net cost comparison shifts in favor of biosimilars. A transparent PBM contract that passes 100% of rebates is essential for making the right Humira decision.